Analysis of the key themes driving private equity deal activity reveals that immuno-oncology accounted for 6 pharmaceutical deals announced in Q2 2023, worth a total value of $82.2m. The $45.5m acquisition of GreenLight Biosciences Holdings PBC by Fall Line Capital in a going private transaction was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q2 2023 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
In value terms, immuno-oncology-related deal activity increased by 319% in Q2 2023 compared with the previous quarter’s total of $19.6m and fell by 53% as compared to Q2 2022. Related deal volume increased by 500% in Q2 2023 versus the previous quarter.
The top-ranked legal advisors supporting these private equity deals in Q2 2023 were Foley Hoag; Goodwin Procter; O'Melveny & Myers with 1, 1, 1 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q2 2023 – Thematic Intelligence, buy the report here.